Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | GLS | O94925 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CTSA | P10619 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090202 | 0.83 | HDAC3 (0.63) | SCN9ASMN1; SMN2MAPK1HDAC3HDAC1 | |
| SCHEMBL2225530 | 0.82 | NPC1 (0.56) | SCN9ASMN1; SMN2RAB9AKMT2APOLB | |
| SCHEMBL6641462 | 0.81 | SMN1; SMN2 (0.48) | SCN9ASMN1; SMN2RAB9AMAPK1KMT2A | |
| SCHEMBL5101919 | 0.80 | HDAC3 (0.65) | SCN9ASMN1; SMN2MAPK1HDAC3HDAC1 | |
| SCHEMBL6634510 | 0.80 | NPC1 (0.56) | RAB9AKMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL5095582 | 0.79 | POLB (0.67) | SCN9ASMN1; SMN2RAB9AKMT2AHDAC3 | |
| SCHEMBL5090143 | 0.79 | NPC1 (0.55) | RAB9AKMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL5090102 | 0.79 | SCN9A (0.56) | SCN9ASMN1; SMN2RAB9AKMT2AHDAC3 | |
| SCHEMBL5095756 | 0.79 | CTSA (0.58) | SMN1; SMN2RAB9AKMT2AHDAC3HDAC1 | |
| SCHEMBL5095610 | 0.79 | NPC1 (0.77) | SMN1; SMN2RAB9AKMT2AHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207677-A1 | Napthyridine Compounds As Rock Inhibitors | GPC BIOTECH AG (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1833832-A1 | NAPTHYRIDINE COMPOUNDS AS ROCK INHIBITORS | GPC Biotech AG (DE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2007060028-A1 | NAPTHYRIDINE COMPOUNDS AS ROCK INHIBITORS | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | WO | disclosed |
| US-6255318-B1 | CYTOMEGLO VIRUS | BIOCHEM PHARMA INC. (CA) | 2001-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207677-A1 | Napthyridine Compounds As Rock Inhibitors | ROCK2, ROCK1, RHOT2 | SCN9A 2561/4885SMN1; SMN2 171/4885GLS 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.